Modulation of the GABAergic pathway for the treatment of fragile X syndrome

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1769-1779

  Lozano, Reymundo ^a,b   Hare, Emma B ^a,b   Hagerman, Randi J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arbaclofen; Autism; Gamma aminobutyric acid (GABA) system; Ganax olone; Targeted treatments

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; ACAMPROSATE; ARBACLOFEN; BASIMGLURANT; BRAIN DERIVED NEUROTROPHIC FACTOR; FRAGILE X MENTAL RETARDATION PROTEIN; G PROTEIN COUPLED RECEPTOR; GABOXADOL; GANAXOLONE; GLUTAMATE RECEPTOR; MAVOGLURANT; METABOTROPIC RECEPTOR; RECEPTOR SUBUNIT; RILUZOLE; TIAGABINE; VIGABATRIN;

ABNORMAL LABORATORY RESULT; AMYGDALOID NUCLEUS; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY; AUTISM; BRAIN REGION; CATABOLISM; CEREBELLUM; CLINICAL TRIAL; CONVULSION; COUGHING; DIARRHEA; DISORIENTATION; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; FEVER; FRAGILE X MENTAL RETARDATION GENE 1; FRAGILE X SYNDROME; GABAERGIC SYSTEM; GENE; GENE MUTATION; HALLUCINATION; HUMAN; INTELLECTUAL IMPAIRMENT; LIMBIC SYSTEM; LIVER FUNCTION TEST; MOUSE; NEOCORTEX; NEUROBIOLOGY; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; OTITIS MEDIA; PHARYNGITIS; REVIEW; SEIZURE; SENSORY STIMULATION; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84907221070     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S42919     Document Type: Review

References (83)

1. Belmonte MK, Bourgeron T. Fragile X syndrome and autism at the intersection of genetic and neural networks. Nat Neurosci. 2006;9(10):1221–1225.
2. Bretherick KL, Fluker MR, Robinson W P. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet. 2005;117(4):376–382.
3. Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ ataxia syndrome. Lancet Neurol. 2013;12(8):786–798.
4. Bourgeois JA, Seritan AL, Casillas EM, et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry. 2011;72(2):175–182.
5. Winarni TI, Chonchaiya W, Sumekar TA, et al. Immune-mediated disorders among women carriers of fragile X premutation alleles. Am J Med Genet A. 2012;158a(10):2473–2481.
6. Au J, Akins RS, Berkowitz-Sutherland L, et al. Prevalence and risk of migraine headaches in adult fragile X premutation carriers. Clin Genet. 2013;84(6):546–551.
7. Hamlin AA, Sukharev D, Campos L, et al. Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet A. 2012;158A(6):1304–1309.
8. Sullivan SD, Welt C, Sherman S. FMR1 and the continuum of primary ovarian insuffciency. Semin Reprod Med. 2011;29(04):299–307.
9. Conde V, Palomar FJ, Lama MJ, et al. Abnormal GABA-mediated and cerebellar inhibition in women with the fragile X premutation. J Neurophysiol. 2013;109(5):1315–1322.
10. Farzin F, Perry H, Hessl D, et al. Autism spectrum disorders and attention-defcit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr. 2006;27(Suppl 2):S137–S144.
11. Leigh MJS, Hagerman R., Hessl D. Fragile X Syndrome. In: Hansen RL, Rogers SJ, editors. Autism and Other Neurodevelopmental Disorders. Arlington: American Psychiatric Publishing; 2013:57–76.
12. Coffee B, Keith K, Albizua I, et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet. 2009;85(4):503–514.
13. Crawford DC, Acuña JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med. 2001;3(5): 359–371.
14. Sorensen PL, Gane LW, Yarborough M, Hagerman R., Tassone F. Newborn screening and cascade testing for FMR1 mutations. Am J Med Genet A. 2013;161(1):59–69.
15. Allen EG, He W, Yadav-Shah M, Sherman SL. A study of the distributional characteristics of FMR1 transcript levels in 238 individuals. Hum Genet. 2004;114(5):439–447.
16. Ludwig AL, Espinal GM, Pretto DI. CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size. Hum Mol Genet. Epub February 11, 2014.
17. Bhakar AL, Dölen G, Bear M F. The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci. 2012;35: 417–443.
18. Brown V, Jin P, Ceman S, et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profles in fragile X syndrome. Cell. 2001;107(4):477–487.
19. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27(7):370-377.
20. Moy SS, Nadler JJ. Advances in behavioral genetics: mouse models of autism. Mol Psychiatry. 2008;13(1):4-26.
21. Rubenstein J, Merzenich M. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003; 2(5):255-267.
22. Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012;122(12): 4314-4322.
23. Fatemi S, Folsom T, Rooney R, Thuras P. Mrna and protein expression for novel GABAA receptors 8 and p2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl Psychiatry. 2013;3(6):e271.
24. Dölen G, Carpenter RL, Ocain TD, Bear MF. Mechanism-based approaches to treating fragile X. Pharmacol Ther. 2010;127(1): 78-93.
25. Berry-Kravis E, Knox A, Hervey C. Targeted treatments for fragile X syndrome. J Neurodev Disord. 2011;3(3):193-210.
26. Padgett CL, Slesinger PA. GABAB receptor coupling to G-proteins and ion channels. Adv Pharmacol. 2010;58:123-147.
27. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci. 2005;6(3): 215-229.
28. Cardin JA, Carlén M, Meletis K, et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature. 2009; 459(7247):663-667.
29. Wang LW, Berry-Kravis E, Hagerman RJ. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics. 2010;7(3): 264–274.
30. Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature. 2009;459(7247):698-702.
31. Berry-Kravis E, Grossman AW, Crnic LS, Greenough WT. Understanding fragile X syndrome. Current Paediatrics. 2002;12(4): 316-324.
32. Hagerman R., Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2009;123(1):378-390.
33. Adusei DC, Pacey LK, Chen D, Hampson DR. Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology. 2010;59(3):167-171.
34. Liao CW, Lien C. Estimating intracellular Ca2+ concentrations and buffering in a dendritic inhibitory hippocampal interneuron. Neuroscience. 2009;164(4):1701-1711.
35. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, Huntsman MM. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci. 2010;30(29):9929-9938.
36. Curia G, Papouin T, Séguéla P, Avoli M. Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cereb Cortex. 2009;19(7):1515-1520.
37. D’Hulst C, Heulens I, Brouwer JR, et al. Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res. 2009;1253:176-183.
38. Gantois I, Vandesompele J, Speleman F, et al. Expression profling suggests underexpression of the GABAA receptor subunit delta in the fragile X knockout mouse model. Neurobiol Dis. 2006;21(2):346-357.
39. Pacey LKK, Heximer SP, Hampson DR. Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile x knockout mice to audiogenic seizures. Mol Pharmacol. 2009;76(1):18-24.
40. Kim SY, Burris J, Bassal F, et al. Fear-specific amygdala function in children and adolescents on the fragile x spectrum: a dosage response of the FMR1 gene. Cereb. Cortex. 2014;24(3):600-613.
41. Gibson JR, Bartley AF, Hays SA, Huber KM. Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J Neurophysiol. 2008;100(5):2615-2626.
42. Berry-Kravis E., Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012;4(152):152ra127.
43. Erickson CA, Weng N, Weiler IJ, et al. Open-label riluzole in fragile X syndrome. Brain Res. 2011;1380:264-270.
44. Erickson CA, Wink LA, Ray B, et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013; 228(1):75-84.
45. Carter RB, Wood PL, Wieland S, et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3[3-hydroxy-3|5-methyl-5a-pregnan-20-one), a selective, high-affinity, steroid modulator of the y-aminobutyric acidA receptor. J Pharmacol Exp Ther. 1997;280(3):1284-1295.
46. Kerrigan JF, Shields WD, Nelson TY, et al. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res. 2000;42(2):133-139.
47. Heulens I, D’Hulst C, Van Dam D, De Deyn PP, Kooy RF. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav Brain Res. 2012;229(1):244–249.
48. D’Hulst C, De Geest N, Reeve SP, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 2006; 1121(1): 238-245.
49. Chang S, Bray SM, Li Z, et al. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol. 2008;4(4):256-263.
50. Pieribone VA, Tsai J, Souffet C, et al. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia. 2007;48(10):1870-1874.
51. Marinus Pharmaceuticals. Ganaxolone Treatment in Children With Fragile X Syndrome. Available from: http://clinicaltrials.gov/ct2/show/ NCT01725152. NLM identifer: NCT01725152. Accessed March 24, 2014.
52. Nusser Z, Mody I. Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells. J Neurophysiol. 2002;87(5): 2624–2628.
53. Cope DW, Hughes SW, Crunelli V GABAA receptor-mediated tonic inhibition in thalamic neurons. J Neurosci. 2005;25(50):11553-11563.
54. Brown N, Kerby J, Bonnert T, Whiting P, Wafford K. Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3) delta GABA(A) receptors. Br J Pharmacol. 2002;136(7):965-974.
55. Wohlfarth KM, Bianchi MT, Macdonald RL. Enhanced neurosteroid potentiation of ternary GABA(A) receptors containing the delta subunit. J Neurosci. 2002;22(5):1541-1549.
56. Haas KF, Macdonald RL. GABAA receptor subunit gamma2 and delta subtypes confer unique kinetic properties on recombinant GABAA receptor currents in mouse fibroblasts. J Physiol. 1999;514(Pt 1):27-45.
57. Deng PY, Rotman Z, Blundon JA, et al. FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels. Neuron. 2013;77(4):696-711.
58. Olmos-Serrano JL, Corbin JG, Burns MP. The GABA(A) receptor agonist THIP ameliorates specifc behavioral defcits in the mouse model of fragile X syndrome. Dev Neurosci. 2011;33(5):395–403.
59. Egawa K, Kitagawa K, Inoue K, et al. Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of angelman syndrome. Sci Transl Med. 2012;4(163):163ra157.
60. Browne, TR. Pharmacokinetics of antiepileptic drugs. Neurology. 1998;51(5 Suppl 4):S2-S7.
61. Browne T, Szabo G. New pharmacokinetic methods for the study of antiepileptic medications of the 1990s. Epilepsia. 1990;32:S66-S73.
62. Lindberger M, Luhr O, Johannessen SI, Larsson S, Tomson T. Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. Ther Drug Monit. 2003;25(4):457-462.
63. Podboraczynska-Jodkoi K, Lubinski W, Hampel-Osipowicz E. Retinal dysfunction in patients treated with vigabatrin. Klin. Oczna. 2007;109(1–3):85–88. Polish.
64. Henderson C, Wijetunge L, Kinoshita MN, et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012; 4(152):152ra128.
65. Thomson, Reuters. Key trial of Seaside autism drug fails to show benefit [press release]. New York, NY: Thomson Reuters; 2013 [May 1]. Available from: http://www.reuters.com/article/2013/05/01/us-autism-drug-idUSBRE9400NT20130501. Accessed May 05, 2014
66. Sansone SM, Widaman KF, Hall SS, et al. Psychometric study of the Aberrant Behavior Checklist in Fragile X Syndrome and implications for targeted treatment. J Autism Dev Disord. 2012;42(7):1377–1392.
67. He Y, Benz A, Fu T, et al. Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology. 2002;42(2):199–209.
68. Leach J P, Brodie MJ. New antiepileptic drugs – an explosion of activity. Seizure. 1995;4(1):5–17.
69. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia. 1995;36(6):612–626.
70. Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJ, Sonnewald U, Braestrup C. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol. 1991; 196(3):257–266.
71. Berry-Kravis E. Epilepsy in fragile X syndrome. Dev Med Child Neurol. 2002;44(11):724–728.
72. National Fragile X Foundation. Seaside Therapeutics Announces End of Arbaclofen (STX209) Extension Study [press release]. Walnut Creek, CA: National Fragile X Foundation; 2013 [May 16]. Available from: http://www.fragilex.org/2013/research/news-reports-and-com-mentaries/seaside-therapeutics-announces-end-of-arbaclofen-stx209-extension-study/. Accessed May 06, 2014.
73. Berry-Kravis E. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome. Pediatr Neurol. 2014;50(4):297–302.
74. Braat S, Kooy R F. Fragile X syndrome neurobiology translates into rational therapy. Drug Discovery Today. 2014;19(4):510–519.
75. Jacquemont S, Curie A, des Portes V, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011;3(64):64ra1.
76. Schneider A, Leigh MJ, Adams P, et al. Electrocortical changes associated with minocycline treatment in fragile X syndrome. J Psychopharmacol. 2013;27(10):956–963.
77. University of California, Los Angeles. Trial to evaluate the safety of Lovastatin in individuals with neurofbromatosis Type I (NF1). Available from: http://clinicaltrials.gov/show/NCT00352599. NLM identifer: NCT00352599. Accessed May 26, 2014.
78. Michalon A, Sidorov M, Ballard TM, et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron. 2012;74(1): 49–56.
79. Chen W. Multitouch tabletop technology for people with autism spectrum disorder: a review of the literature. Procedia Comput Sci. 2012;14:198–207.
80. Winarni TI, Schneider A, Borodyanskara M, Hagerman RJ. Early intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile x syndrome. Case Rep Genet. 2012;2012:280813.
81. Leigh MJ, Nguyen D V, Mu Y, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr. 2013;34(3):147–155.
82. Dziembowska M, Pretto DI, Janusz A, et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A. 2013;161A(8):1897–1903.
83. Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5(2):145–150.